<DOC>
	<DOCNO>NCT01491490</DOCNO>
	<brief_summary>Olanzapine one effective best tolerated atypical antipsychotic , also particularly associate weight gain metabolic problem . This study conduct GW Pharma Ltd pilot study order determine efficacy safety two medication GW42003 GW42004 40:1 ratio combine subject exist treatment olanzapine subject weight gain attributable olanzapine treatment functional psychosis . This first study determine whether study medication positive benefit subject cholesterol level , body weight metabolic parameter , well potential augmentation anti-psychotic effect olanzapine . This multi-centre randomise , double-blind , placebo-controlled , parallel-group pilot study . There two group subject ( GWP42003 plus GWP42004 ( 40:1 ratio ) placebo ) , treatment duration 6 week well baseline period variable length one week follow-up . The two treatment group randomise equally . In order eligible enrollment study , subject need age 18 year clinically diagnose functional psychosis receive olanzapine treatment 3 month evidence weight gain attributable olanzapine treatment . Eligible subject enter study screen visit ( Visit 1 ) commence baseline period . Subjects also assess Visit 2 weight gain baseline period . The baseline period flexible length allow time weight gain achieve also olanzapine dose stabilise . If eligible subject randomise 6-week treatment phase . There total 6 visit study .</brief_summary>
	<brief_title>Treatment Iatrogenic Weight Gain Dyslipidaemia Associated With Olanzapine</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Weight Gain</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Diagnosis ( DSMIV ) schizophrenia functional psychosis include schizophreniform acute psychosis schizophrenia symptom Receiving olanzapine treatment 3 month The dose olanzapine stable least 2 week prior randomisation ( Visit 2 ) subject willing maintain stable dose olanzapine duration study Evidence weight gain last 3 month attributable olanzapine , prior screen ( Visit 1 ) . Wherever possible , investigator must exclude possible cause weight gain , change exercise , diet , illnesses Each subject must weight gain attributable olanzapine , baseline period ( Visits 1 2 ) 5 month subsequent commencement olanzapine treatment Willing maintain stable dose concomitant medication , stable dose minimum 6 week ( exception olanzapine ) No change diet exercise 6 week prior screen ( Visit 1 ) subject agree maintain stability , duration study ( opinion investigator ) Subject Axis I ( DSMIV ) diagnosis schizoaffective disorder ; Subject drug induce toxic psychosis ( opinion investigator ) Subject present clinical picture and/ history consistent delirium , dementia , amnesia cognitive disorder ; bipolar disorder major depression Subject significant history anxiety , suicidal ideation selfharm base history routine psychiatric status examination ( opinion investigator ) Subject unstable thyroid pathology ( include hypo hyperthyroidism ) , within past six month ( opinion investigator ) Subject history neuroleptic malignant syndrome ; Subject require electroconvulsive therapy ( ECT ) treatment 2 month period prior randomisation ( Visit 2 ) Subject clinical diagnosis diabetes Subject take insulin ( i.e . insulin dependent ) insulin within 6 month prior screen visit ( Visit 1 ) ; Any know suspected history ( opinion investigator ) : alcohol substance abuse epilepsy recurrent seizures Any known suspect history depression sufficient require treatment disrupt ordinary life ( exclude episode reactive depression opinion investigator ) BDI Score â‰¥ 15 ( Visit 1 2 ) Clinically significant cardiac , renal hepatic impairment opinion investigator Genetic dyslipidaemic condition opinion investigator Female patient childbearing potential male patient whose partner childbearing potential , unless willing ensure partner use effective contraception , example , oral contraception , double barrier , intrauterine device , study three month thereafter ( however , male condom use conjunction female condom may prove effective ) Travel outside country residence plan study treatment period Having receive olanzapine treatment continuously 3 month prior screen ( Visit 1 ) Received Investigational Medicinal Product within 90 day screen visit ( Visit 1 ) Any significant disease disorder , opinion investigator , may either put subject risk participation study , influence result study , subject 's ability participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Functional psychosis</keyword>
	<keyword>Schizophreniform</keyword>
	<keyword>Acute psychosis</keyword>
</DOC>